Crucial US Advisory Committee to Vote on Altering Baby Hepatitis B Vaccine Guideline
Following a delay and an unusually contentious session, a national immunization advisory committee was scheduled to decide on Friday regarding a potential change to the enduring advisory that every infant be vaccinated against hepatitis B.
Fiery Exchange and a Deferred Vote
The first day of the assembly on Thursday was characterized by fiery discussion over limiting availability to the hepatitis B vaccine for newborns and a decision to defer the vote by a day to give members more time to review the wording. The committee, which guides the CDC on immunization practices, had put off the vote twice in the past.
“Is there any concrete proof of damage of giving this vaccination before 30 days? Or is this conjecture?” inquired one panel member.
In answer, another participant stated, “There is inadequate data about the enduring danger.”
Current Guidelines and Likely Ramifications
The shot is currently suggested for all infants within 24 hours of birth to halt contraction of hepatitis B, which can cause major damage to the liver. It has been provided to 1.4 billion people for more than three decades.
The Georgia assembly offered no recent proof of damage attributable to the vaccine. Experts say any modification to the current hepatitis B vaccine regimen could have profound and widespread implications for childhood health in the United States.
Panel Composition and Recent Changes
The advisory panel can only offer guidance to the leader of the CDC. The group's roster has experienced alterations in recent days, with the announcement that the panel's latest chairman would depart for an official role and be succeeded by a cardiologist who has been questioning of other vaccines.
The committee includes a number of immunization doubters who support a aim to revamp – and possibly, in some cases, abolish – traditional vaccination recommendations.